Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure (ReProsperHF)
Systolic Heart Failure
About this trial
This is an interventional treatment trial for Systolic Heart Failure focused on measuring heart failure, ejection fraction equal or less than 40%
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- EF < 40% via echocardiogram within the past 12 months
- Stable dose of heart failure medications for > past 1 month
- NYHA class II - IV
Exclusion Criteria
- Pregnant or lactating female
- Receiving IV inotrope
- History of significant non-compliance
- Unwilling to adhere to the protocol
- Systemic systolic BP less than 90 mmHg at screening visit
- History of allergy to probenecid
- History of gout
- History of renal calculi
- Recent unstable coronary artery syndromes (USA, admission to hospital for AMI, revascularization procedure, or acute decompensated HF requiring hospitalization) within the past 3 months.
- Implant of CRT device within the past 3 months
- TIA, CVA or major surgery within the past 3 months
- Valvular heart disease (more than moderate stenosis or insufficiency)
- HOCM, myocarditis, constrictive pericarditis, congenital heart disease, 14 Active chemotherapy, significant malignancy or uncontrolled metabolic disease (untreated hyper or hypothyroidism, Cushing's disease etc.)What about uncontrolled DM?? HgA1C > etc
15. Elevated liver enzymes (> 3 times ULN), 16. Current atrial fibrillation or frequent PVCs (should we define this now) 17. End stage renal disease (dialysis dependent) or worsening renal insufficiency should define now.
18. History of gastric ulcerations, significant gastroesophageal reflux. 19. Other condition that in the opinion of the investigator, would make the subject a poor candidate for the study.
20. Co-administration of any medication that in the opinion of the investigator places the subject at increased risks due to potential adverse drug interactions.
Sites / Locations
- University of Cincinnati
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Probenecid
placebo
Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.